| A new rapid desensitization protocol for chemotherapy agents G Gastaminza, JM Borbolla, MJ Goikoetxea, R Escudero, J Anton, ... ESMON Publicidad, 2011 | 57 | 2011 |
| Dendritic cell vaccination in glioblastoma after fluorescence-guided resection RD Valle, ALD de Cerio, S Inoges, S Tejada, F Pastor, H Villanueva, ... World journal of clinical oncology 3 (11), 142, 2012 | 28 | 2012 |
| A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer R MartÍNez-Monge, M GaztaÑAga, JM AramendÍA, M Cambeiro, L Arbea, ... International Journal of Gynecologic Cancer 20 (1), 2010 | 17 | 2010 |
| Tratamiento hormonal del cáncer de mama J Espinós, C Reyna, S de la Cruz Revista de Medicina de la Universidad de Navarra, 40-48, 2008 | 10 | 2008 |
| Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with … JP Fusco, E Castañón, OE Carranza, L Zubiri, P Martín, J Espinós, ... Journal of neuro-oncology 115, 429-435, 2013 | 9 | 2013 |
| Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report J Bosch-Barrera, J Espinós International Archives of Medicine 3, 1-3, 2010 | 8 | 2010 |
| Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive … Y Nieto, JM Aramendía, J Espinós, S De la Cruz, O Fernández-Hidalgo, ... Cancer chemotherapy and pharmacology 65, 457-465, 2010 | 5 | 2010 |
| Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone J Bosch-Barrera, J Espinós, A Gómez-Ibáñez, J Gállego Pérez-Larraya, ... Clinical and Translational Oncology 11, 765-766, 2009 | 5 | 2009 |
| Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? I Garrido-Laguna, M Ponz, J Espinós Journal of clinical oncology 25 (9), 1149-1149, 2007 | 4 | 2007 |
| El factor von Willebrand como intermediario entre la hemostasia y la angiogénesis de origen tumoral I Gil-Bazo, V Catalan, J Páramo, C Quero, SE de Romaní, A Pérez-Ochoa, ... Revista de Medicina de la Universidad de Navarra, 22-28, 2003 | 3 | 2003 |
| Dual-time point FDG imaging greatly improves the diagnosis of incidental uptake in the abdomino-pelvic area P Garrastachu, M Garcia-Velloso, I Dominguez, E Martino, J Espinos, ... Journal of Nuclear Medicine 49 (supplement 1), 350P-350P, 2008 | 1 | 2008 |
| Neoadjuvant chemotherapy based on dose-dense epirubicin (E) plus cyclophosphamide (C) followed by docetaxel (D) plus trastuzumab (T), DT plus carboplatin (CBDCA), or DT plus … L Ceniceros, L Murillo Jaso, N Rodríguez-Spiteri, E Castanon Alvarez, ... Journal of Clinical Oncology 33 (15_suppl), e11617-e11617, 2015 | | 2015 |
| 37th Annual San Antonio Breast Cancer Symposium. Resumen de las aportaciones translacionales y clínicas más relevantes M Santisteban, S de la Cruz, J Espinós, JM Aramendía, ... Revista de Senología y Patología Mamaria 28 (2), 85-89, 2015 | | 2015 |
| GEINOFOTE: Safety and activity analysis of the use of fotemustine (FT) in different schedules in progressive high-grade glioma (HGG) in Spain. P Pérez-Segura, R Manneh Kopp, I Ceballos, A Garcia, M Benavides, ... Journal of Clinical Oncology 32 (15_suppl), 2055-2055, 2014 | | 2014 |
| Impact of vascular endothelial growth factor (VEGF), D-dimer (DD) and plasminogen activator inhibitor-1 (PAI-1) levels on clinical outcome in stage IV colorectal cancer (CRC) I Gil-Bazo, J Rodriguez, V Catalan, A Alonso, J De la Camara, J Espinos, ... ANNALS OF ONCOLOGY 15, 85-85, 2004 | | 2004 |
Marta Ferrer PugaDepartment of Allergy, Clinica Universidad de NavarraVerified email at unav.es
